Highlights From: 9th Annual International Congress on Hematologic Malignancies February 2005, Whistler, BC, Canada, 41st Annual Meeting of the American Society of Clinical Oncology May 2005, Orlando, FL, 46th Annual Meeting of the American Society of Hematology December 2004, San Diego, CA
- 1 June 2005
- journal article
- Published by Elsevier BV in Clinical Lymphoma
- Vol. 6 (1), 4-10
- https://doi.org/10.1016/s1526-9655(11)70110-5
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- A phase II study of Epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin’s lymphomasJournal of Clinical Oncology, 2005
- Phase I trial of siplizumab in CD2-positive lymphoproliferative diseaseJournal of Clinical Oncology, 2005
- Targeting the microtubule apparatus in indolent and mantle cell lymphoma with the novel epothilone anlog BMS 247550 induces major and durable remissions in very drug resistant diseaseJournal of Clinical Oncology, 2005
- Histone deacetylase inhibitors and cancer: from cell biology to the clinicEuropean Journal of Cell Biology, 2005
- Epothilones: Mechanism of Action and Biologic ActivityJournal of Clinical Oncology, 2004
- Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8–mediated apoptosis and down-regulation of c-FLIP proteinBlood, 2003
- Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507Blood, 2003
- Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridolBiochemical and Biophysical Research Communications, 2002
- Mechanisms of action of flavopiridolCritical Reviews in Oncology/Hematology, 2001
- Primary Cutaneous T-Cell Lymphoma: Review and Current ConceptsJournal of Clinical Oncology, 2000